✦ LIBER ✦

MYELOSUPPRESSION AFTER METHOTREXATE, MITOZANTRONE, AND MITOMYCIN C COMBINATION CHEMOTHERAPY

✍ Scribed by Powles, TrevorJ.; Ashley, Susan

Book ID: 121888033
Publisher: The Lancet
Year: 1987
Tongue: English
Weight: 159 KB
Volume: 330
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(87)91035-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

MYELOSUPPRESSION AFTER METHOTREXATE, MIT

MYELOSUPPRESSION AFTER METHOTREXATE, MITOZANTRONE, AND MITOMYCIN C FOR TREATMENT OF ADVANCED BREAST CANCER

✍ Marks, Annabella; Goodman, Andrew; Dougherty, Shona; Ashford, Richard 📂 Article 📅 1987 🏛 The Lancet 🌐 English ⚖ 168 KB

MYELOSUPPRESSION AFTER METHOTREXATE, MIT

MYELOSUPPRESSION AFTER METHOTREXATE, MITOXANTRONE, AND MITOMYCIN C

✍ Jodrell, DuncanI.; Iveson, TimJ.; Smith, IanE. 📂 Article 📅 1987 🏛 The Lancet 🌐 English ⚖ 166 KB

MYELOTOXICITY OF METHOTREXATE, MITOZANTR

MYELOTOXICITY OF METHOTREXATE, MITOZANTRONE, AND MITOMYCIN C

✍ Morton, A.R.; Anderson, H.; Howell, A. 📂 Article 📅 1987 🏛 The Lancet 🌐 English ⚖ 167 KB

Unexpected prolonged myelosuppression af

Unexpected prolonged myelosuppression after mitomycin, mitoxantrone and methotrexate

✍ Muhonen, Timo T.; Wiklund, Tom A.; Blomqvist, Carl P.; Pyrhönen, Seppo O. 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 382 KB

A randomised trial comparing combination

A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer

✍ Powles, TJ; Jones, AL; Judson, IR; Hardy, JR; Ashley, SE 📂 Article 📅 1991 🏛 Nature Publishing Group 🌐 English ⚖ 901 KB

Mitomycin C, melphalan and methotrexate

Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer

✍ D. J. Perez; T. J. Powles; J. -C. Gazet; H. T. Ford; R. C. Coombes 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 299 KB

Fifty-seven patients with metastatic breast carcinoma have been treated with mitomycin C (10 mg/m2 IV 6-weekly), melphalan (6 mg/m2 PO X 3 days, 3-weekly), and methotrexate (35 mg/m2 IV 3-weekly) to assess the efficacy and toxicity of this regimen. Of 48 evaluable patients 19 (40%) responded for a m